ACOR News and Press, Acorda Therapeutics Inc. From 10/18/18

Acorda Therapeutics (NASDAQ: ACOR ) is up  8%  premarket on light volume on the heels of its disclosure that the FDA's pre-approval inspections of its Chelsea, MA manufacturing facility and the Inbrija inhaler device maker's facility have been completed with no further action req...

NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SunOpta, Inc. (NASDAQ:STKL), Acorda Therapeutics, Inc. (NASDAQ:ACOR), Sap...

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its third quarter 2018 update and financial results on Wednesday, October 31 at 8:30 a.m. ET. To participate in the conference call, please dial (833) 236-2756 (domestic) or (647) 689-4181 (int...

InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present a new post-hoc efficacy analysis from SPAN-PD, the pivotal Phase 3 trial of INBRIJA, at the upcoming International Congress of Parkinson’s Disease and Movement Disorders ® taking place October 5-9, 2018 in Hong Kong. INBR...